Home or Home-like Hospital Birth
1 other identifier
observational
500
1 country
1
Brief Summary
In the Netherlands, which has about 200.000 births per year, maternity care is provided by midwives or general practitioners unless medical reasons necessitate specialist obstetric care. Women with low risk pregnancies are free to decide where to give birth, attended by their midwife or general practitioner, at home or in the hospital, from which they are then discharged within 24 hours. In the Netherlands these hospital births are referred to as "poliklinische bevallingen" (i.e. outpatient deliveries) to indicate that they do not involve formal hospitalisation, or as "verplaatste thuisbevalling" (i.e. relocated home births) to indicate that they are supervised by the same caregivers as the home births without involvement of specialist obstetricians. In the last two decades a marked increase in the referral rate to obstetricians during childbirth has occurred, especially for nulliparae, both in planned home births and planned hospital births (outpatient deliveries). 90% from all primigravidae will start their pregnancy under care of the primary caregiver (midwife of general practitioner). During the pregnancy 30% will be referred to the secondary caregiver (obstetrician specialist). The other 60% will start labor guided by the primary caregiver. More than 50% of these women will be referred to the obstetrician during labor. Despite this unique situation of the Dutch maternity care, the differences between home and hospital birth (outpatient deliveries) with regard to effectivity and efficiency have never been investigated. It is also unclear if pregnant women are informed about a 50% risk of being transported to the secondary caregiver/ hospital during labor at home. Neither do we know what their experiences are. This study aims to investigate the differences between home and hospital deliveries under care of the primary caregiver with regard to effectivity (costs) and efficiency (patient satisfaction) of care.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2006
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 7, 2005
CompletedFirst Posted
Study publicly available on registry
October 12, 2005
CompletedStudy Start
First participant enrolled
January 1, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2008
CompletedApril 2, 2010
April 1, 2010
2.2 years
October 7, 2005
April 1, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
primary outcome: referral rate to secondary care, preferences of women and partners with regard to place of birth. Secondary outcome: costs of home birth and hospital births satisfaction of obstetric care
Study Arms (2)
1
Women with the intention to give birth at home
2
Women with the intention to give birth in a short-stay hospital setting
Interventions
Eligibility Criteria
Women with a low-risk pregnancy under the care of an independent midwife. Women are free to choose where to give birth, at home or in a short-stay hospital setting. The women are fluent in de Dutch language.
You may qualify if:
- Primiparae
- No medical indication for specialistic care
- The pregnant woman will be able to give birth at home or at a hospital
- The woman and her partner will be fluent in the Dutch language
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Academic Hospital Maastricht
Maastricht, 6202 HX, Netherlands
Related Publications (1)
Aldana-Bitar J, Moore J, Manubolu VS, Dahal S, Verghese D, Lakshmanan S, Hussein L, Crabtree T, Jonas R, Min JK, Earls JP, Budoff MJ. Plaque Progression Differences Between Apixaban and Rivaroxaban in Patients With Atrial Fibrillation Measured With Cardiac Computed Tomography and Plaque Quantification. Am J Ther. 2023 Jul-Aug 01;30(4):e313-e320. doi: 10.1097/MJT.0000000000001569. Epub 2022 Oct 18.
PMID: 36731003DERIVED
Study Officials
- STUDY CHAIR
Jan G. Nijhuis, Prof dr MD PhD
Maastricht University Medical Center
- PRINCIPAL INVESTIGATOR
Marijke JC Hendrix, MBA
Maastricht University Medical Center
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
October 7, 2005
First Posted
October 12, 2005
Study Start
January 1, 2006
Primary Completion
March 1, 2008
Study Completion
December 1, 2008
Last Updated
April 2, 2010
Record last verified: 2010-04